REGN3500

DRUG5 trials

Sponsors

Regeneron Pharmaceuticals

Conditions

AsthmaAsthma, AllergicAtopic DermatitisHealthy VolunteersModerate Asthma

Phase 1

A Study of Intravenously or Subcutaneously Administered REGN3500 in Healthy Adult Subjects

CompletedNCT02958436

Regeneron PharmaceuticalsHealthy Volunteers

Start: 2016-08-31End: 2017-10-03Updated: 2017-11-08

Study of Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of REGN3500 in Adults With Moderate Asthma

CompletedNCT02999711

Regeneron PharmaceuticalsAsthma, Moderate Asthma

Start: 2017-02-03End: 2018-09-10Updated: 2018-12-12

Study of REGN3500 and Dupilumab in Patients With Asthma

CompletedNCT03112577

Regeneron PharmaceuticalsAsthma, Allergic

Start: 2017-06-15End: 2019-12-09Updated: 2020-01-18

Phase 2

Efficacy and Safety of REGN3500 Monotherapy and Combination of REGN3500 Plus Dupilumab in Adult Patients With Moderate-to-Severe Atopic Dermatitis

TerminatedNCT03736967

Regeneron PharmaceuticalsAtopic Dermatitis

Start: 2018-11-12End: 2020-07-28Updated: 2021-11-01

Efficacy, Safety, and Pharmacokinetic Profiles of REGN3500 Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis

TerminatedNCT03738423

Regeneron PharmaceuticalsAtopic Dermatitis

Start: 2018-11-13End: 2020-07-24Updated: 2022-06-10

Related Papers

Efficacy and safety of tozorakimab in moderate‐to‐severe atopic dermatitis: A Phase 2a randomized controlled trial (<scp>FRONTIER</scp>‐2)

Journal of the European Academy of Dermatology and Venereology2024-11-136 citations

Pharmacokinetics and pharmacodynamics of itepekimab in adults with moderate‐to‐severe atopic dermatitis: Results from two terminated phase II trials

Clinical and Translational Science2024-07-309 citations